Nuvalent, Inc. 4

Chief Medical Officer Christopher Durant Turner tendered 31,530 Nuvalent Class A shares at $124.00 and had all RSUs, PSUs, and stock options fully cashed out in the GSK acquisition, leaving him with no remaining holdings.

On July 15, 2026, in connection with the cash acquisition of Nuvalent, Inc. by GlaxoSmithKline at $124.00 per share, Chief Medical Officer Christopher Durant Turner tendered 31,530 shares of Class A Common Stock into the offer for cash, and all of his outstanding equity awards were cashed out per the Merger Agreement. This included the cancellation of 41,100 time-based RSUs and multiple tranches of vested and unvested stock options with exercise prices ranging from $6.89 to $106.82, each converted into cash equal to the spread (if any) over the $124.00 offer price, as well as 14,350 performance stock units that vested at closing and were similarly converted to cash. Following these transactions, Turner reported no remaining equity holdings in Nuvalent, reflecting a complete monetization of his equity as the company became a wholly owned subsidiary of GlaxoSmithKline.

Filing Facts

CIK

1861560

Ticker

NUVL

Form

4

Source Type

fda

Accession

0001193125-26-305073

Alert Tier

7